| 10.17.24 | Sage shrinks R&D team by half; Kezar spurns buyout offer, adopts poison pill

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

1 Monat vor

Html
Text

IQVIA eCOA. Amplifying the patient’s voice

IQVIA eCOA expert, Edward Bartels, walks through the capabilities and key features of the IQVIA eCOA platform. Watch the demo to explore functionalities from study design, eDiary and questionnaire design, and active study management.

Today’s Big News

Oct 17, 2024

Sage lays off half of R&D team, shakes up C-suite again

Kezar rejects Concentra bid that 'substantially undervalues' the biotech

Novartis pays China's Baiyu $70M upfront, with $1.1B chaser, for small molecule cancer candidate

Sanofi returns to Orano with €300M for radioligand 'pioneer' project

Terray assembles $120M series B to push AI-powered small molecules into clinic

Noema ticks off phase 2a Tourette win for ex-Roche molecule

Clario and PathAI partner up to create streamlined workflow for gastrointestinal clinical trials

Unlocking the Untapped Potential of the Patient Perspective in Rare Disease Clinical Trials

Patient perspectives, priorities, and preferences – without these criteria, designing truly patient-centric rare disease trials is impossible. Turn up the volume of the patient voice on your next study with the help of our guide.

Featured

Sage lays off half of R&D team, shakes up C-suite again

By James Waldron

Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading for the exits along with a swath of the company’s leadership.

Kezar rejects Concentra bid that 'substantially undervalues' the biotech

By James Waldron

Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra Biosciences.

Novartis pays China's Baiyu $70M upfront, with $1.1B chaser, for small molecule cancer candidate

By Nick Paul Taylor

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. The deal, which features $1.1 billion in milestones, covers the global rights to a small molecule discovered by a Chinese biotech that has built a business around botanical drugs.

Revolutionizing gene therapy logistics with Cryoport's Elite solution

Sanofi returns to Orano with €300M for radioligand 'pioneer' project

By James Waldron

The new entity, which will operate under the Orano Med brand, will be focused on discovering and developing next-generation radioligand therapies based on lead-212 alpha-emitting isotopes.

The sudden progress in rare kidney disease is built on years of dedication

Terray assembles $120M series B to push AI-powered small molecules into clinic

By Gabrielle Masson

Terray Therapeutics has raked in $120 million for a series B fundraise as the AI-focused biotech aims to transform small molecule drug development.

Noema ticks off phase 2a Tourette win for ex-Roche molecule

By Nick Paul Taylor

Noema Pharma has racked up a phase 2a win for its Tourette syndrome drug candidate, reporting hits on the primary and key secondary endpoints in a small study of the former Roche molecule.

Clario and PathAI partner up to create streamlined workflow for gastrointestinal clinical trials

By Darren Incorvaia

Clinical data company Clario and AI firm PathAI are teaming up to create an end-to-end imaging and pathology workflow for gastrointestinal clinical trials.

Compounds from healthy vaginal bacteria show promise as inflammation treatment

By Darren Incorvaia

The vaginal microbiome hasn’t received as much attention as the one in the gut, but it is known to influence health.

3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy Vyalev

By Zoey Becker

The 24-hour Parkinson's disease therapy crossed the FDA finish line after an initial manufacturing-related rejection last year and another snub in June.

NIH study shows Bavarian Nordic's mpox shot elicits immune response in teens

By Kevin Dunleavy

With the clade 1 outbreak of mpox raging through parts of Africa, interim results of an NIH trial of Bavarian Nordic's Jynneos indicate that it is safe and elicits an immune response in adolescents.

Fierce podcasts

Don’t miss an episode

A revival in neuro therapeutics

This week on "The Top Line," Fierce Pharma's Fraiser Kansteiner chats with industry leaders about the surge in neuroscience investment, breakthroughs and future targets in neuropharmaceuticals.

How HIV prevention stays out of reach for many

Breaking down BIOSECURE—Industry implications and what comes next


A message from cresset

Resources

eBook

Decoding the data

Need the superpowers to select the right lab equipment?

Sponsored by: PHC Corporation of North America

Whitepaper

Strategies to Optimize Expression Challenges of Multi-chain and Bispecific Antibodies

Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects.

Communicating the Value of Biopharma Assets to Potential Investors

How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights.

Presented by: Blue Matter

Whitepaper

Accelerating Timelines to Clinic with GPEx® Lightning

Unlock the Future of Biotherapeutics with Catalent Biologics!

Epilepsy Clinical Trials

Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner.